Clinical Trial Update: Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response [Phase 3]

View source ↗

Summary

Phase III trial assessing a dose adjustment of imatinib mesylate for molecular response in chronic-phase myeloid leukemia; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: Institut Bergonié | Conditions: Leukemia, Myeloid, Chronic-Phase | Phase 3 | Status: TERMINATED | Results posted: 2020-12-31